跳到正文
openFDA 已分级药品召回执法报告·· 26 天前精选AI 评分64

FDA 执法报告 D-0049-2027 将 Viatris 替米沙坦氨氯地平片超效价召回列为 III 类

FDA drug enforcement D-0049-2027: Viatris, Inc. — Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications

AI 导读

openFDA 执法报告 D-0049-2027 记录 Viatris 公司自愿召回替米沙坦氨氯地平片 40mg/5mg(30 片/瓶),原因是相关批次替米沙坦含量可能超出标准,属于超效价风险,被列为 III 类。

推荐理由

记录给出了超效价风险涉及的具体批号、有效期与分销范围,可用于核对召回边界与批次覆盖。

正文 · 原文

FDA drug recall enforcement report — D-0049-2027

Report issued: 2026-10-28. This is the enforcement report date, not the recall initiation date.

Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.

The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.

Complete official product record (including openFDA harmonized identifiers):

{

"address_1": "3711 Collins Ferry Rd",

"address_2": "",

"center_classification_date": "20261016",

"city": "Morgantown",

"classification": "Class III",

"code_info": "Lot # 3228113, 3228114, 3228115, Exp Date: Oct 31, 2026; Lot # 3228120, 3228121, Exp Date: Nov 30, 2026.",

"country": "United States",

"distribution_pattern": "Nationwide in the USA.",

"event_id": "100048",

"initial_firm_notification": "Letter",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA202516"

],

"brand_name": [

"TELMISARTAN AND AMLODIPINE"

],

"generic_name": [

"TELMISARTAN AND AMLODIPINE"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Mylan Pharmaceuticals Inc."

],

"nui": [

"N0000000070",

"N0000175561"

],

"package_ndc": [

"0378-1075-93",

"0378-1076-93",

"0378-1077-93",

"0378-1078-93"

],

"pharm_class_epc": [

"Angiotensin 2 Receptor Blocker [EPC]"

],

"pharm_class_moa": [

"Angiotensin 2 Receptor Antagonists [MoA]"

],

"product_ndc": [

"0378-1075",

"0378-1076",

"0378-1077",

"0378-1078"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"ORAL"

],

"rxcui": [

"876514",

"876519",

"876524",

"876529"

],

"spl_id": [

"c4f4323d-671d-478b-b088-008530932cee"

],

"spl_set_id": [

"ca60a4d5-ace7-4889-94ee-e2265fd63811"

],

"substance_name": [

"TELMISARTAN",

"AMLODIPINE BESYLATE"

],

"unii": [

"U5SYW473RQ",

"864V2Q084H"

],

"upc": [

"0303781075930",

"0303781076937",

"0303781078931",

"0303781077934"

]

},

"postal_code": "26505-2362",

"product_description": "Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India, NDC 0378-1075-93.",

"product_quantity": "21,620 30-count bottles",

"product_type": "Drugs",

"reason_for_recall": "Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications",

"recall_initiation_date": "20261001",

"recall_number": "D-0049-2027",

"recalling_firm": "Viatris, Inc.",

"report_date": "20261028",

"state": "WV",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov